BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hamilton BA, Wright JF. Challenges Posed by Immune Responses to AAV Vectors: Addressing Root Causes. Front Immunol 2021;12:675897. [PMID: 34084173 DOI: 10.3389/fimmu.2021.675897] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Goedeker NL, Dharia SD, Griffin DA, Coy J, Truesdale T, Parikh R, Whitehouse K, Santra S, Asher DR, Zaidman CM. Evaluation of rAAVrh74 gene therapy vector seroprevalence by measurement of total binding antibodies in patients with Duchenne muscular dystrophy. Ther Adv Neurol Disord 2023;16:17562864221149781. [PMID: 36710722 DOI: 10.1177/17562864221149781] [Reference Citation Analysis]
2 Romano M, Squeglia F, Kramarska E, Barra G, Choi HG, Kim HJ, Ruggiero A, Berisio R. A Structural View at Vaccine Development against M. tuberculosis. Cells 2023;12. [PMID: 36672252 DOI: 10.3390/cells12020317] [Reference Citation Analysis]
3 Chen X, Wolfe DA, Sivadasan Bindu D, Zhang M, Taskin N, Goertsen D, Shay TF, Sullivan E, Huang SF, Ravindra Kumar S, Arokiaraj CM, Plattner V, Campos LJ, Mich J, Monet D, Ngo V, Ding X, Omstead V, Weed N, Bishaw Y, Gore B, Lein ES, Akrami A, Miller C, Levi BP, Keller A, Ting JT, Fox AS, Eroglu C, Gradinaru V. Functional gene delivery to and across brain vasculature of systemic AAVs with endothelial-specific tropism in rodents and broad tropism in primates. bioRxiv 2023:2023. [PMID: 36711773 DOI: 10.1101/2023.01.12.523844] [Reference Citation Analysis]
4 Guide SV, Gonzalez ME, Bağcı IS, Agostini B, Chen H, Feeney G, Steimer M, Kapadia B, Sridhar K, Quesada Sanchez L, Gonzalez F, Van Ligten M, Parry TJ, Chitra S, Kammerman LA, Krishnan S, Marinkovich MP. Trial of Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis Bullosa. N Engl J Med 2022;387:2211-9. [PMID: 36516090 DOI: 10.1056/NEJMoa2206663] [Reference Citation Analysis]
5 Shen W, Liu S, Ou L. rAAV immunogenicity, toxicity, and durability in 255 clinical trials: A meta-analysis. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1001263] [Reference Citation Analysis]
6 Cacicedo ML, Weinl-tenbruck C, Frank D, Limeres MJ, Wirsching S, Hilbert K, Pasha Famian MA, Horscroft N, Hennermann JB, Zepp F, Chevessier-tünnesen F, Gehring S. Phenylalanine hydroxylase mRNA rescues the phenylketonuria phenotype in mice. Front Bioeng Biotechnol 2022;10:993298. [DOI: 10.3389/fbioe.2022.993298] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Aubert M, Haick AK, Strongin DE, Klouser LM, Loprieno MA, Stensland L, Santo TK, Huang M, Hyrien O, Stone D, Jerome KR. AAV-delivered gene editing for latent genital or orofacial herpes simplex virus infection reduces ganglionic viral load and minimizes subsequent viral shedding in mice.. [DOI: 10.1101/2022.09.23.509057] [Reference Citation Analysis]
8 Ren D, Fisson S, Dalkara D, Ail D. Immune Responses to Gene Editing by Viral and Non-Viral Delivery Vectors Used in Retinal Gene Therapy. Pharmaceutics 2022;14:1973. [PMID: 36145721 DOI: 10.3390/pharmaceutics14091973] [Reference Citation Analysis]
9 Yang T, Braun M, Lembke W, Mcblane F, Kamerud J, Dewall S, Tarcsa E, Fang X, Hofer L, Kavita U, Upreti VV, Gupta S, Loo L, Johnson AJ, Chandode RK, Stubenrauch K, Vinzing M, Xia CQ, Jawa V. Immunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paper. Molecular Therapy - Methods & Clinical Development 2022;26:471-94. [DOI: 10.1016/j.omtm.2022.07.018] [Reference Citation Analysis]
10 Gehrke M, Diedrichs-Möhring M, Bogedein J, Büning H, Michalakis S, Wildner G. Immunogenicity of Novel AAV Capsids for Retinal Gene Therapy. Cells 2022;11:1881. [PMID: 35741009 DOI: 10.3390/cells11121881] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Li J, Kelly SC, Ivey JR, Thorne PK, Yamada KP, Aikawa T, Mazurek R, Turk JR, Silva KAS, Amin AR, Tharp DL, Mueller CM, Thakur H, Leary EV, Domeier TL, Rector RS, Fish K, Cividini F, Ishikawa K, Emter CA, Kapiloff MS. Distribution of cardiomyocyte-selective adeno-associated virus serotype 9 vectors in swine following intracoronary and intravenous infusion. Physiol Genomics 2022. [PMID: 35648460 DOI: 10.1152/physiolgenomics.00032.2022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Atasheva S, Shayakhmetov DM. Cytokine Responses to Adenovirus and Adenovirus Vectors. Viruses 2022;14:888. [DOI: 10.3390/v14050888] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Schoser B. [Principles of translational gene therapy for neuromuscular diseases]. Nervenarzt 2022. [PMID: 35384490 DOI: 10.1007/s00115-022-01287-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Kishimoto TK, Samulski RJ. Addressing high dose AAV toxicity - 'one and done' or 'slower and lower'? Expert Opin Biol Ther 2022;:1-5. [PMID: 35373689 DOI: 10.1080/14712598.2022.2060737] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
15 Prosseda PP, Tran M, Kowal T, Wang B, Sun Y. Advances in Ophthalmic Optogenetics: Approaches and Applications. Biomolecules 2022;12:269. [DOI: 10.3390/biom12020269] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
16 Unnisa Z, Yoon JK, Schindler JW, Mason C, van Til NP. Gene Therapy Developments for Pompe Disease. Biomedicines 2022;10:302. [DOI: 10.3390/biomedicines10020302] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
17 Kagiava A, Richter J, Tryfonos C, Leal-Julià M, Sargiannidou I, Christodoulou C, Bosch A, Kleopa KA. Efficacy of AAV serotypes to target Schwann cells after intrathecal and intravenous delivery. Sci Rep 2021;11:23358. [PMID: 34857831 DOI: 10.1038/s41598-021-02694-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
18 Yu DL, Chow NSM, Bridle BW, Wootton SK. Macrophage Depletion via Clodronate Pretreatment Reduces Transgene Expression from AAV Vectors In Vivo. Viruses 2021;13:2002. [PMID: 34696433 DOI: 10.3390/v13102002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]